Modulators of androgen synthesis
The present specification discloses compositions comprising at least one therapeutic compound capable of modulating androgen production and methods and uses for treating a disorder associated with androgen production using such compositions and/or compounds.
1. A method of treating an individual with a lung cancer, the method comprising the step of administering to the individual a therapeutically effective amount of risperidone and about 0.01 mg/kg/day to about 0.5 mg/kg/day of 9Z, 11E conjugated Linoleic acid,
wherein there is a synergistic effect between risperidone and 9Z, 11E conjugated Linoleic Acid; and
wherein administration the risperidone and the 9Z, 11E conjugated Linoleic acid reduces a symptom associated with the lung cancer, thereby treating the individual.
2. The method according to claim 1 , wherein the therapeutically effective amount of risperidone is from about 0.1 mg/day to about 20 mg/day.
3. The method according to claim 1 , wherein the therapeutically effective amount of risperidone is from about 0.01 mg/kg/day to about 0.5 mg/kg/day.
4. The method according to claim 1 , wherein 9Z, 11E conjugated Linoleic acid is in an amount from about 1 mg/day to about 20 mg/day.
5. The method according to claim 1 , wherein the lung cancer is a non-small cell lung adenocarcinoma.
6. The method according to claim 1 , wherein risperidone and 9Z, 11E conjugated Linoleic Acid are sequentially or simultaneously administered to the individual as separate compositions.
7. The method according to claim 1 , wherein risperidone and 9Z, 11E conjugated Linoleic Acid are administered as a single composition to the individual.
8. A method of treating an individual with a lung cancer, the method comprising the step of administering to the individual a therapeutically effective amount of risperidone and about 1 mg/day to about 20 mg/day of 9Z, 11E conjugated Linoleic Acid, wherein there is a synergistic effect between the risperidone and 9Z, 11 E conjugated Linoleic Acid; and wherein administration of risperidone and 9Z, 11E conjugated Linoleic acid reduces a symptom associated with the lung cancer, thereby treating the individual.
9. The method according to claim 8 , wherein the therapeutically effective amount of risperidone is in an amount from about 0.1 mg/day to about 20 mg/day.
10. The method according to claim 8 , wherein the therapeutically effective amount of risperidone is in an amount from about 0.01 mg/kg/day to about 0.5 mg/kg/day.
11. The method according to claim 8 , wherein 9Z, 11E conjugated Linoleic acid is in an amount from about 0.01 mg/kg/day to about 0.5 mg/kg/day.
12. The method according to claim 8 , wherein the lung cancer is a non-small cell lung adenocarcinoma.
13. The method according to claim 8 , wherein risperidone and 9Z, 11E conjugated Linoleic Acid are sequentially or simultaneously administered to the individual as separate compositions.
14. The method according to claim 8 , wherein risperidone and 9Z, 11E conjugated Linoleic Acid are administered as a single composition to the individual.
15. A method of treating an individual with a lung cancer, the method comprising the step of administering to the individual about 1 mg/day to about 20 mg/day of risperidone and about 1 mg/day to about 20 mg/day of 9Z, 11E conjugated Linoleic acid,
wherein there is a synergistic effect between risperidone and 9Z, 11E conjugated Linoleic Acid; and
wherein administration risperidone and 9Z, 11E conjugated Linoleic acid reduces a symptom associated with the lung cancer, thereby treating the individual.
16. The method according to claim 15 , wherein the lung cancer is a non-small cell lung adenocarcinoma.
17. The method according to claim 15 , wherein risperidone and 9Z, 11E conjugated Linoleic Acid are sequentially or simultaneously administered to the individual as separate compositions.
18. The method according to claim 15 , wherein risperidone and 9Z, 11E conjugated Linoleic Acid are administered as a single composition to the individual.
19. The method according to claim 15 , wherein the therapeutically effective amount of risperidone is from about 0.01 mg/kg/day to about 0.5 mg/kg/day.
20. The method according to claim 15 , wherein 9Z, 11E conjugated Linoleic acid is in an amount from about 0.01 mg/kg/day to about 0.5 mg/kg/day.
21. A method of treating an individual with a lung cancer, the method comprising the step of administering to the individual about 0.01 mg/kg/day to about 0.5 mg/kg/day of risperidone and about 0.01 mg/kg/day to about 0.5 mg/kg/day of 9Z, 11E conjugated Linoleic acid,
wherein there is a synergistic effect between risperidone and 9Z, 11E conjugated Linoleic Acid; and
wherein administration risperidone and 9Z, 11E conjugated Linoleic acid reduces a symptom associated with the lung cancer, thereby treating the individual.
22. The method according to claim 21 , wherein risperidone is in an amount from about 0.1 mg/day to about 20 mg/day.
23. The method according to claim 21 , wherein 9Z, 11E conjugated Linoleic acid is in an amount from about 1 mg/day to about 20 mg/day.
24. The method according to claim 21 , wherein the lung cancer is a non-small cell lung adenocarcinoma.
25. The method according to claim 21 , wherein risperidone and 9Z, 11E conjugated Linoleic Acid are sequentially or simultaneously administered to the individual as separate compositions.
26. The method according to claim 21 , wherein risperidone and 9Z, 11E conjugated Linoleic Acid are administered as a single composition to the individual.